PROVEN PERFORMANCE

As therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with ribociclib in postmenopausal women as initial endocrine-based therapy or following disease progression on ET, or in combination with palbociclib or abemaciclib in women with disease progression after ET.1

PROVEN PERFORMANCE

As therapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with ribociclib in postmenopausal women as initial endocrine-based therapy or following disease progression on ET, or in combination with palbociclib or abemaciclib in women with disease progression after ET.1

As monotherapy for the treatment of HR-positive advanced breast cancer in postmenopausal women who have endocrine therapy-naïve, HER2-negative disease (FALCON), or disease progression following endocrine therapy (CONFIRM)1

ET=endocrine therapy; HER2=human epidermal growth factor receptor 2; HR=hormone receptor; mBC=metastatic breast cancer.

Reference: 1. FASLODEX® (fulvestrant) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.